Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rupesh Manam

Internal Medicine Winston Salem, NC Medical Doctor

NPI 1184079519 CMS profile 5705555

186 Kimel Park Dr, Winston Salem, NC 27103

Open in the dashboard

General payments

$6,886

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rupesh Manam of Winston Salem, NC is reported in the CMS Open Payments database as having received $6,886 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,198 21
2024 General $751 15
2023 General $2,082 44
2022 General $812 19
2021 General $715 7
2020 General $252 2
2019 General $75 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rupesh Manam
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rupesh Manam were reported at $2,198. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rupesh Manam Internal Medicine median Middle half National median
2019 $75 $159 $48–$570 $163
2020 $252 $119 $33–$402 $114
2021 $715 $135 $37–$521 $132
2022 $812 $141 $42–$496 $149
2023 $2,082 $149 $45–$519 $160
2024 $751 $154 $47–$537 $164
2025 $2,198 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,748 26 payments
  2. Boston Scientific Corporation $1,015 10 payments
  3. HeartFlow, Inc. $503 4 payments
  4. Biotronik Inc. $247 3 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $221 4 payments
  6. Medtronic, Inc. $203 4 payments
  7. E.R. Squibb & Sons, L.L.C. $196 26 payments
  8. Amgen Inc. $143 6 payments
  9. Novartis Pharmaceuticals Corporation $129 6 payments
  10. Novo Nordisk Inc $103 5 payments
  11. Other $378 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,730 97 payments
  2. Travel and Lodging $3,003 11 payments
  3. Education $152 1 payment
Products named General payments · program years 2019–2025
  1. TRICLIP $1,808 12 payments
  2. MITRACLIP Vascular $1,468 7 payments
  3. FFRct $503 4 payments
  4. WATCHMAN Structural Heart $469 4 payments
  5. MITRACLIP Vascular $320 6 payments
  6. WATCHMAN Access System $290 3 payments
  7. WATCHMAN Watchman $182 2 payments
  8. Ensite Cardiac Mapping System $152 1 payment
  9. Acticor 7 VR-T DX $136 2 payments
  10. LEQVIO $129 6 payments
  11. Other $1,470 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

3,741

Median for Cardiology: 2,533

Drug cost

$589,921

Median for Cardiology: $485,213

Branded share of claims

33.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 366 $278,952
Jardiance Empagliflozin Brand 134 $106,750
Entresto Sacubitril/Valsartan Brand 99 $87,901
Repatha Sureclick Evolocumab Brand 80 $48,388
Xarelto Rivaroxaban Brand 31 $26,618
Ranolazine Er Ranolazine Brand 89 $7,449
Praluent Pen Alirocumab Brand 14 $6,698
Metoprolol Succinate Generic 443 $3,953
Rosuvastatin Calcium Generic 386 $3,829
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 330 $3,351

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$59,542

Medicare's payments for the services billed

Medicare patients

568

Average age 75

Services billed

1,363

280 women, 288 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 53%
Atrial fibrillation 48%
Chronic kidney disease 43%
Diabetes 41%
Heart failure 40%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $108
$108 134 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $46
$46 — —
Wegovy
  • Novo Nordisk Inc $25
$25 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $22
$22 99 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record